Methyldopa.txt CLINICAL USE Hypertension DOSE IN NORMAL RENAL FUNCTION 250 mg 2–3 times a day, increasing to a maximum dose of 3 g daily PHARMACOKINETICS Molecular weight                           :238.2 %Protein binding                           :<15 %Excreted unchanged in urine     : 25–40 Volume of distribution (L/kg)       :0.5 half-life – normal/ESRD (hrs)      :1.6–2/6–16 DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 20 to 50     : Dose as in normal renal function and adjust according to response 10 to 20     : Dose as in normal renal function and adjust according to response <10           : Dose as in normal renal function and adjust according to response DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES CAPD                :Dialysed. Dose as in GFR <10           : mL/min HD                     :Dialysed. Dose as in GFR <10           : mL/min HDF/high flux   :Dialysed. Dose as in GFR <10           : mL/min CAV/VVHD      :Probably dialysed. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect Antidepressants: avoid concomitant use with MAOIs Lithium: neurotoxicity (without increased plasma-lithium concentrations)Salbutamol: acute hypotension reported with salbutamol infusions ADMINISTRATION Reconstition– Route Oral Rate of Administration –Comments– OTHER INFORMATION Active metabolites with long half-life Interferes with serum creatinine measurementOrthostatic hypotension more common in renally impaired patients. Tags: post-by-auto-php Continue Reading Previous Previous post: MESENTERIC ADENITIS.txtNext Next post: Mitomycin.txt Related News sotalol hydrochloride.txt tazocin.txt